Partners

EASL
View details

EASL

WHY DOES EASL EXIST?

THE CREATION OF EASL

The European Association for the Study of the Liver started as a small group of 70 hepatologists from 15 European countries who came together to share best medical practice in April 1966.
50 years later EASL has evolved into a major European Association with international influence dedicated to the liver and liver disease. 
EASL has over 4,000 members from all over the world and provides an annual platform, The International Liver Congress™, for 11,000 liver experts to meet and discuss latest scientific research. 
EASL has given rise to many international clinical trials and research collaborations to the benefit of patients all over the world.
EASL VISION
Many Ways, One Aim: Beating Liver Disease
OUR MISSION
To be the Home of Hepatology so that all who are involved with liver disease can realize their full potential to cure and prevent it.

  • Promotes research in the science of liver disease (Hepatology)
  • Provides state-of-the-art education for physicians and scientists
  • Fosters public awareness of liver diseases and their management
  • Acts as an advisor to European Health authorities
  • Facilitates scientific exchanges and catalyzes European multi-center controlled trials
  • Supports young investigators to ensure that the liver remains at the forefront of research

 

SECRETARY GENERAL

DR. LAURENT CASTERA

Laurent Castera (MD, PhD) graduated from Paris Medical School in 1987 and completed his residency in Hepatology and Gastroenterology in Assistance Publique-Hôpitaux de Paris until 1993 when he received his Medical degree from the University of Paris-VI.
He further completed his training in Hepatology as Assistant Professor in the department of Hepatology and Gastroenterology at the University of Paris-XI (Hôpital Bicêtre) until 1997. Then he spent three years as a research fellow at the INSERM Unit 99 in the laboratory of Prof. Jean-Michel Pawlotsky (Hôpital Henri Mondor, Créteil) where he worked on different aspects of hepatitis viruses resistance to antiviral therapy, using a quasispecies approach.
He earned his Doctoral degree in Biochemistry and Molecular Biology from the University of Paris-XII in 2007. Meanwhile, he was appointed Médecin des Hôpitaux in 2001 and moved to the department of Hepatology and Gastroenterology of the University Hospital of Bordeaux where he started to develop clinical research on novel approaches for the non-invasive evaluation of liver fibrosis, based on the measurement of liver stiffness using transient elastography.
In 2011, Dr Castera joined the department of Hepatology at the University of Paris-VII (Hôpital Beaujon, Clichy) to take the lead of the non-invasive methods and the HCC group. The same year he organised with Prof. Massimo Pinzani the EASL Monothematic Conference on Evaluation of Disease Severity and Prognosis in Chronic Liver Disease.
Laurent Castera is member of the American Association for the Study of Liver Disease (AASLD) and of the French Association for the Study of the Liver (AFEF). He serves on the editorial boards of the Journal of Hepatology and Gut and as a member of the Scientific Committee of the United European Gastroenterology (UEG) since 2011. He became member of the EASL Governing Board in April 2012.

ELPA
correlation
EMCDDA